Host factor-targeted hepatitis B virus therapies

Intervirology

Volumn 57, Issue 3-4, 2014, Pages 158-162

  Gehring, Adam J ^a,b   Bertoletti, Antonio ^c,d   Tavis, John E ^a,b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Saint Louis University   (United States)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

^d AGENCY FOR SCIENCE   (Singapore)

Author keywords

Hepatitis B virus; Immunotherapy; Therapy

Indexed keywords

ALPHA INTERFERON; CIRCULAR DNA; GAMMA INTERFERON; HOST FACTOR; NUCLEOSIDE ANALOG; ANTIVIRUS AGENT; HEPATITIS B HYPERIMMUNE GLOBULIN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IMMUNOGLOBULIN; VIRUS DNA; VIRUS RNA;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; CELLULAR IMMUNITY; DNA REPLICATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA VIRUS; T LYMPHOCYTE; VIRUS REPLICATION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; HEPATITIS B, CHRONIC; IMMUNOLOGY; PROCEDURES; VIRION;

ANTIVIRAL AGENTS; DNA, VIRAL; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOGLOBULINS; IMMUNOTHERAPY; INTERFERON-ALPHA; INTERFERON-GAMMA; VIRUS REPLICATION;

HEPATITIS B VIRUS;

EID: 84904690558     PISSN: 03005526     EISSN: 14230100     Source Type: Journal    
DOI: 10.1159/000360938     Document Type: Review

References (53)

1. Marcellin P, Gane E, Buti M, et al: Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381: 468-475.
2. Zoulim F, Perrillo R: Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol 2008; 48:S2-S19.
3. Boni C, Laccabue D, Lampertico P, et al: Restored function of HBV-specific T cells after long-term effective therapy with nucleos( t)ide analogues. Gastroenterology 2012; 143: 963-973.e9.
4. Woo G, Tomlinson G, Nishikawa Y, et al: Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 2010; 139: 1218-1229.
5. Wursthorn K, Jung M, Riva A, et al: Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology 2010; 52: 1611-1620.
6. van Bommel F, de Man RA, Wedemeyer H, et al: Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleos(t)ide analogues. Hepatology 2009; 51: 73-80.
7. Guidotti LG: Viral clearance without destruction of infected cells during acute HBV infection. Science 1999; 284: 825-829.
8. Werle Lapostolle B, Bowden S, Locarnini S, et al: Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126: 1750-1758.
9. Lutgehetmann M, Volz T, Kopke A, et al: In vivo proliferation of hepadnavirus-infected hepatocytes induces loss of covalently closed circular DNA in mice. Hepatology 2010; 52: 16-24.
10. Fox AN, Terrault NA: The option of HBIGfree prophylaxis against recurrent HBV. J Hepatol 2012; 56: 1189-1197.
11. Volz T, Allweiss L, Ben MBarek M, et al: The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol 2013; 58: 861-867.
12. Petersen J, Dandri M, Mier W, et al: Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol 2008; 26: 335- 341.
13. Meier A, Mehrle S, Weiss TS, Mier W, Urban S: Myristoylated PreS1-domain of the hepatitis B virus L-protein mediates specific binding to differentiated hepatocytes. Hepatology 2013; 58: 31-42.
14. Mao R, Nie H, Cai D, et al: Inhibition of hepatitis B virus replication by the host zinc finger antiviral protein. PLoS Pathog 2013; 9:e1003494.
15. Liang G, Kitamura K, Wang Z, et al: RNA editing of hepatitis B virus transcripts by activation- induced cytidine deaminase. Proc Natl Acad USA 2013; 110: 2246-2251.
16. Suspene R, Guetard D, Henry M, Sommer P, Wain-Hobson S, Vartanian JP: Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc Natl Acad Sci USA 2005; 102: 8321-8326.
17. Vartanian JP, Henry M, Marchio A, et al: Massive APOBEC3 editing of hepatitis B viral DNA in cirrhosis. PLoS Pathog 2010; 6:e1000928.
18. Bonvin M, Achermann F, Greeve I, et al: Interferon- inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication. Hepatology 2006; 43: 1364-1374.
19. Baumert TF, Rosler C, Malim MH, von Weizsacker F: Hepatitis B virus DNA is subject to extensive editing by the human deaminase APOBEC3C. Hepatology 2007; 46: 682- 689.
20. Nguyen DH, Gummuluru S, Hu J: Deamination- independent inhibition of hepatitis B virus reverse transcription by APOBEC3G. J Virol 2007; 81: 4465-4472.
21. Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, et al: Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 2014;343:1221- 1228.
22. Hu J, Flores D, Toft D, Wang X, Nguyen D: Requirement of heat shock protein 90 for human hepatitis B virus reverse transcriptase function. J Virol 2004; 78: 13122-13131.
23. Hu J, Seeger C: Hsp90 is required for the activity of a hepatitis B virus reverse transcriptase. Proc Natl Acad Sci USA 1996; 93: 1060- 1064.
24. Jhaveri K, Modi S: HSP90 inhibitors for cancer therapy and overcoming drug resistance. Adv Pharmacol 2012; 65: 471-517.
25. Cai D, Mills C, Yu W, et al: Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation. Antimicrob Agents Chemother 2012; 56: 4277- 4288.
26. Mao R, Zhang J, Jiang D, et al: Indoleamine 2,3-dioxygenase mediates the antiviral effect of gamma interferon against hepatitis B virus in human hepatocyte-derived cells. J Virol 2010; 85: 1048-1057.
27. McCaffrey AP, Nakai H, Pandey K, et al: Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol 2003; 21: 639- 644.
28. Morrissey DV, Lockridge JA, Shaw L, et al: Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 2005; 23: 1002-1007.
29. Wooddell CI, Rozema DB, Hossbach M, et al: Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol Ther 2013; 21: 973-985.
30. Perrillo R: Benefits and risks of interferon therapy for hepatitis B. Hepatology 2009; 49(5 suppl):S103-S111.
31. Allweiss L, Volz T, Lutgehetmann M, Giersch K, Bornscheuer T, Lohse AW, et al.: Immune cell responses are not required to induce substantial hepatitis B virus antigen decline during pegylated interferon-alpha administration. J Hepatol 2014;60:500-507.
32. Liu F, Campagna M, Qi Y, et al: Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes. PLoS Pathog 2013; 9:e1003613.
33. Belloni L, Allweiss L, Guerrieri F, et al: IFN inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest 2012; 122: 529-537.
34. Lutgehetmann M, Bornscheuer T, Volz T, et al: Hepatitis B virus limits response of human hepatocytes to interferon in chimeric mice. Gastroenterology 2011; 140: 2074-2083.e1-2.
35. Tan AT, Hoang LT, Chin D, et al: Reduction of HBV replication prolongs the early immunological response to IFN therapy. J Hepatol 2014; 60: 54-61.
36. Micco L, Peppa D, Loggi E, et al: Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. J Hepatol 2013; 58: 225-233.
37. Ji C, Sastry KS, Tiefenthaler G, et al: Targeted delivery of interferon to hepatitis B virusinfected cells using T-cell receptor-like antibodies. Hepatology 2012; 56: 2027-2038.
38. Penna A, Laccabue D, Libri I, et al: Peginterferon does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis. J Hepatol 2012; 56: 1239-1246.
39. Isogawa M, Robek MD, Furuichi Y, Chisari FV: Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol 2005; 79: 7269-7272.
40. Kimura K, Kakimi K, Wieland S, Guidotti LG, Chisari FV: Activated intrahepatic antigenpresenting cells inhibit hepatitis B virus replication in the liver of transgenic mice. J Immunol 2002; 169: 5188-5195.
41. McClary H, Koch R, Chisari FV, Guidotti LG: Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines. J Virol 2000; 74: 2255-2264.
42. Lanford RE, Guerra B, Chavez D, et al: GS- 9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology 2013; 144: 1508-1517.e1- 10.
43. Tang XZ, Jo J, Tan AT, et al: IL-7 licenses activation of human liver intrasinusoidal mucosal- associated invariant T cells. J Immunol 2013; 190: 3142-3152.
44. Bertoletti A, Gehring AJ: Immune therapeutic strategies in chronic hepatitis B virus infection: virus or inflammation control? PLoS Pathog 2013:19;9:e1003784.
45. Liu J, Zhang E, Ma Z, Wu W, Kosinska A, Zhang X, et al: Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection. PLoS Pathog 2014: 2;10:e1003856.
46. Tan AT, Loggi E, Boni C, et al: Host ethnicity and virus genotype shape the hepatitis B virus- specific T-cell repertoire. J Virol 2008; 82: 10986-10997.
47. Kidd-Ljunggren K, Miyakawa Y, Kidd AH: Genetic variability in hepatitis B viruses. J Gen Virol 2002; 83: 1267-1280.
48. Gehring AJ, Haniffa M, Kennedy PT, et al: Mobilizing monocytes to cross-present circulating viral antigen in chronic infection. J Clin Invest 2013; 123: 3766-3776.
49. Xu DZ, Wang XY, Shen XL, et al: Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings. J Hepatol 2013; 59: 450-456.
50. Isogawa M, Chung J, Murata Y, Kakimi K, Chisari FV: CD40 activation rescues antiviral CD8+ T cells from PD-1-mediated exhaustion. PLoS Pathog 2013; 9:e1003490.
51. Huang LR, Wohlleber D, Reisinger F, et al: Intrahepatic myeloid-cell aggregates enable local proliferation of CD8+ T cells and successful immunotherapy against chronic viral liver infection. Nat Immunol 2013; 14: 574- 583.
52. Tavis JE, Gehring AJ, Hu Y: How further suppression of virus replication could improve current HBV treatment. Expert Rev Anti Infect Ther 2013; 11: 755-757.
53. Block TM, Gish R, Guo H, et al: Chronic hepatitis B: what should be the goal for new therapies? Antivir Res 2013; 98: 27-34.